Option Care Health
OPCH
31.01
+0.01
+0.03%
Option Care Health
US · OPCH
#2386 by market cap
Listed 1970
31.01
+0.01
+0.03%
Live - 5344 symbols - heartbeat 299s ago
· 2026-10-08 07:00
Pre-market
30.94
-0.23%
After-hours
31.04
+0.10%
Overnight
30.71
-0.97%
- Market cap
- 4.65B
- P/E (TTM)i
- 23.49
- P/Bi
- 3.69
- EPSi
- 1.27
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on OPCH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.3 percentage points.
Institutional ownership
- Held by institutions
- 48.34% -1.27pp
- Institutions
- 103 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund45.15%
Insurance Company1.70%
Individual/Insider1.39%
Sovereign Wealth Fund1.31%
Hedge Fund0.11%
Other50.28%
Top holders
Wellington Management Group
7.94%
Vanguard Capital Management, LLC
5.42%
Vanguard Portfolio Management, LLC
5.38%
Fuller & Thaler Asset Management, Inc.
4.76%
State Street Global Advisors
3.92%
Geode Capital Management, LLC
2.84%
Dimensional Fund Advisors
2.59%
Charles Schwab Investment Management
1.66%
Boston Partners Global Investors, Inc.
1.62%
Norges Bank Investment Management
1.31%
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| John Rademacher | Chief Executive Officer | 0.46% |
| Harry M. Kraemer | Independent Non Executive Chairman of the Board | 0.30% |
| Michael Shapiro | Chief Financial Officer | 0.18% |
| Luke Whitworth | Chief Operating Officer | 0.07% |
| David Golding | Independent Director | 0.07% |
| Meenal Sethna | Chief Financial Officer | 0.07% |
| Timothy Sullivan | Independent Director | 0.06% |
| John Arlotta | Independent Director | 0.04% |
| Collin Smyser | General Counsel | 0.03% |
| Nicole Maggio | Principal Accounting Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-05 | Prateek Bhatia | -- | Other Acquisition | +39,795 | -- |
| 2026-05-19 | Timothy Sullivan | Independent Director | Other Acquisition | +13,833 | $22.23 |
| 2026-05-19 | Eric Brandt | Director | Other Acquisition | +11,640 | $22.23 |
| 2026-05-19 | Harry M. Kraemer | Independent Non Executive Chairman of the Board | Other Acquisition | +8,997 | -- |
| 2026-05-19 | Harry M. Kraemer | Independent Non Executive Chairman of the Board | Other Acquisition | +12,079 | $22.23 |
| 2026-05-19 | R. Pate | Independent Director | Other Acquisition | +8,997 | -- |
| 2026-05-19 | Elizabeth Bierbower | Independent Director | Other Acquisition | +8,997 | -- |
| 2026-05-19 | Barbara Bodem | Director | Other Acquisition | +8,997 | -- |
| 2026-05-19 | Norman Wright | Director | Other Acquisition | +8,997 | -- |
| 2026-05-19 | Natasha Deckmann | Independent Director | Other Acquisition | +9,841 | $22.23 |
| 2026-05-18 | Collin Smyser | General Counsel | Derivative Exercise and Sale | -360 | $20.86 |
| 2026-05-18 | Collin Smyser | General Counsel | Derivative Exercise and Retained | +452 | -- |
| 2026-05-06 | Timothy Sullivan | Independent Director | Open Market Acquisition | +24,154 | $20.69 |
| 2026-05-03 | Harry M. Kraemer | Independent Non Executive Chairman of the Board | Open Market Acquisition | +36,610 | $21.41 |
| 2026-05-03 | John Rademacher | Chief Executive Officer | Open Market Acquisition | +12,500 | $21.18 |
| 2026-05-03 | Meenal Sethna | Chief Financial Officer | Open Market Acquisition | +16,225 | $20.16 |
| 2026-04-21 | Femi Adewunmi | Chief Medical Officer | Sale to Issuer | -1,396 | $28.38 |
| 2026-02-26 | R. Pate | Independent Director | Open Market Disposition | -30,287 | $32.05 |
| 2026-02-26 | Michael Bavaro | Chief Human Resources & Diversity Officer | Open Market Disposition | -6,000 | $33.00 |
| 2026-02-25 | R. Pate | Independent Director | Intent to Sell (Form 144) | -30,287 | $31.89 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:08 · For reference only, not investment advice and not tailored to your situation.